LANREOTIDE

Brand name:

• Somatuline® Autogel

Pharmaceutical company:

IPSEN PTY LTD

Condition/indication:
(therapeutic use)

• Acromegaly Functional Carcinoid Tumour Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)

PBAC Submission type:

Change to existing listing (Category 3)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2024

Related medicines:

--

Submission received for:

July 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 10/07/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

05/08/2024

Lodgement of required documentation:

12/08/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 05/09/2024

Status:

Finalised

Government processes:

Commenced on 05/09/2024

Medicine listed on the PBS:

01/11/2024 (see PBS schedule)

---